Therapy News and Research

RSS

Study explores thoughts among accredited physical therapy schools on pain education

A study published in The Journal of Pain showed that just 2 of 3 accredited physical therapy (PT) schools surveyed believe their students receive adequate education in pain management.

27 Feb 2015

Researchers discover that cell's skeleton can trigger cell multiplication

A research team from Instituto Gulbenkian de Ciencia (IGC; Portugal), led by Florence Janody, in collaboration with Nicolas Tapon from London Research Institute (LRI; UK), discovered that the cell's skeleton can trigger the multiplication of cells through the action of proteins that control cellular rigidity.

27 Feb 2015

EORTC researchers review potential treatment options for patients with locally advanced breast cancer

Treating patients with locally advanced inoperable breast cancer is an extremely difficult task. The overwhelming majority of patients treated for this disease suffer relapse and, despite the best multimodal treatment, do not survive. There is a medical need to examine current and potential treatments, and EORTC researchers have recently published an article in Nature Reviews Clinical Oncology concerning this topic.

27 Feb 2015

Researchers report that 15% of pancreatic cancer patients may benefit from personalized therapies

Cancer researchers at Indiana University report that about 15 percent of people with pancreatic cancer may benefit from therapy targeting a newly identified gene signature.

27 Feb 2015

New online tool helps educate practicing oncologists with therapeutic decision-making for NSCLC

A new interactive online tool helps educate practicing oncologists worldwide with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC) based on a patient's molecular and clinical characteristics by providing feedback from an expert panel.

26 Feb 2015

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region.

26 Feb 2015

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO).

26 Feb 2015

Noble Hospital surgeon to present work on new breast cancer device at Miami Breast Cancer Conference

A Noble Hospital breast surgeon's work with a new device that improves treatment of breast cancers will be featured later this month at a prestigious international medical conference.

26 Feb 2015

HeartWare International's revenue increases 38% to $73.2 million in Q4 2014

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $73.2 million for the fourth quarter ended December 31, 2014, a 38% increase compared to $53.1 million in revenue for the same period of 2013. For the fiscal year 2014, the company generated revenue of $278.4 million, a 34% increase compared to revenue of $207.9 million in 2013.

26 Feb 2015

RowanSOM researcher awarded NINDS grant to develop stem cell-based therapy for Canavan disease

Paola Leone, PhD, the director of the Cell and Gene Therapy Center and a professor of Cell Biology at the Rowan University School of Osteopathic Medicine, has been awarded a three-year, $477,000 grant from the National Institute of Neurological Disorders and Stroke to develop a stem cell-based therapy for Canavan disease, a rare but devastating neurological disorder in children that typically takes a child's life by age 10.

26 Feb 2015

Cherenkov Effect can help make radiation therapy safer, more effective for patients with cancer

The characteristic blue glow from a nuclear reactor is present in radiation therapy, too. Investigators from Dartmouth's Norris Cotton Cancer Center, led by Brian W. Pogue, PhD, and PhD candidates Adam K. Glaser and Rongxiao Zhang, published in Physics in Medicine and Biology how the complex parts of the blue light known as the Cherenkov Effect can be measured and used in dosimetry to make therapies safer and more effective.

26 Feb 2015

Scientists discover DNA vaccine that alleviates chronic inflammation in the body

An international team of scientists including CureLab Oncology, Inc. (Boston), University of Camerino (Italy), and Boston University have serendipitously discovered a DNA vaccine, which systemically alleviates chronic inflammation in the body. Since osteoporosis is an inflammatory disease, preventive and therapeutic effects of the new vaccine were demonstrated on mouse models with osteoporosis.

26 Feb 2015

Scientists use graphene to target, neutralise cancer stem cells

University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells.

25 Feb 2015

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Treatment outcomes were largely similar for the 17 patients with AR-V7-positive prostate cancer and the 20 patients with AR-V7-negative disease included in this analysis.

25 Feb 2015

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).

25 Feb 2015

Researchers develop revolutionary approach to treat drug-resistant tumors

In greater than 90 percent of cases in which treatment for metastatic cancer fails, the reason is that the cancer is resistant to the drugs being used. To treat drug-resistant tumors, doctors typically use multiple drugs simultaneously, a practice called combination therapy.

25 Feb 2015

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

There are no effective available treatments for sufferers of Glioblastoma multiforme (GBM), the most aggressive and devastating form of brain tumor. The disease, always fatal, has a survival rate of only 6-18 months.

25 Feb 2015

Study: Gene variant linked to increased risk of vincristine-induced peripheral neuropathy in children

Children with acute lymphoblastic leukemia who had a certain gene variant experienced a higher incidence and severity of peripheral neuropathy after receiving treatment with the cancer drug vincristine, according to a study in the February 24 issue of JAMA.

25 Feb 2015

Study finds new approaches to manage anticoagulant-associated intracerebral hemorrhage

Among patients with oral anticoagulation-associated intracerebral hemorrhage (bleeding within the brain), reversal of international normalized ratio (INR; a measure used to determine the clotting tendency of blood while on medication) below a certain level within 4 hours and systolic blood pressure less than 160 mm Hg at 4 hours were associated with lower rates of hematoma (a localized swelling filled with blood) enlargement, and resumption of anticoagulant therapy was associated with a lower risk of ischemic events without increased bleeding complications, according to a study in the February 24 issue of JAMA.

25 Feb 2015

Reslizumab drug appears to reduce risk of severe asthma attacks

An investigational drug appears to cut the risk of severe asthma attacks in half for patients who have difficulty controlling the disorder with standard medications, according to results from two multicenter clinical trials.

25 Feb 2015

Therapy News and Research

Study explores thoughts among accredited physical therapy schools on pain education

Researchers discover that cell's skeleton can trigger cell multiplication

EORTC researchers review potential treatment options for patients with locally advanced breast cancer

Researchers report that 15% of pancreatic cancer patients may benefit from personalized therapies

New online tool helps educate practicing oncologists with therapeutic decision-making for NSCLC

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Noble Hospital surgeon to present work on new breast cancer device at Miami Breast Cancer Conference

HeartWare International's revenue increases 38% to $73.2 million in Q4 2014

RowanSOM researcher awarded NINDS grant to develop stem cell-based therapy for Canavan disease

Cherenkov Effect can help make radiation therapy safer, more effective for patients with cancer

Scientists discover DNA vaccine that alleviates chronic inflammation in the body

Scientists use graphene to target, neutralise cancer stem cells

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Researchers develop revolutionary approach to treat drug-resistant tumors

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

Study: Gene variant linked to increased risk of vincristine-induced peripheral neuropathy in children

Study finds new approaches to manage anticoagulant-associated intracerebral hemorrhage

Reslizumab drug appears to reduce risk of severe asthma attacks

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News